News

Sun Pharmaceutical Industries Limited submitted a confirmation certificate dated October 3, 2026, received from MUFG Intime India Private Limited, its Registrar & Share Transfer Agent, pertaining to the quarter ended September 30, 2026, as per Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.

Sun Pharmaceutical Industries Limited will close its trading window for share transactions starting October 1, 2026, and continuing until 48 hours after the declaration of unaudited financial results for the quarter and half year ended September 30, 2026, according to a filing with the National Stock Exchange of India Limited and BSE Limited.

Sun Pharmaceutical Industries announced that CRISIL has removed the `Rating Watch with Developing Implications` status and has reaffirmed the rating assigned to the Company`s long-term bank facilities at `CRISIL AAA/Stable` (Reaffirmed; Removed from `Rating Watch with Developing Implications`).

Net profit of Sun Pharmaceutical Industries rose 27.04% to Rs 2894.79 crore in the quarter ended June 2026 as against Rs 2278.63 crore during the previous quarter ended June 2025. Sales rose 10.14% to Rs 15183.55 crore in the quarter ended June 2026 as against Rs 13786.07 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales15183.5513786.07 10 OPM %29.1031.20 - PBDT5041.624691.32 7 PBT4302.903990.77 8 NP2894.792278.63 27 Powered by Capital Market - Live News

Sun Pharmaceutical Industries announced that the stockholders of Organon & Co. (Organon) have approved the proposals in connection with the previously announced merger transaction under which Organon is expected to become a wholly owned subsidiary of Sun Pharmaceutical Holdings USA, Inc., an indirect wholly owned subsidiary of Sun Pharma. The shareholder approval marks an important milestone towards completion of the proposed transaction. The acquisition remains subject to the satisfaction of the remaining customary closing conditions, including applicable regulatory approvals.